Monash Health Department of Neurosurgery, Australia.
Department of Pathology, Monash Medical Centre, Melbourne, Australia.
J Clin Neurosci. 2020 Nov;81:161-166. doi: 10.1016/j.jocn.2020.09.033. Epub 2020 Oct 10.
Tumour to tumour metastasis is a rare event, especially in the pituitary. Metastases to pituitary adenomas most commonly occurs in late stage disease, commonly presenting with visual field defects and adenohypophyseal dysfunction. The most frequent primary cancers are lung, breast and renal carcinoma which deposit most commonly in prolactinomas, somatotropinomas, gonadotropinomas. In nearly 40% of cases, sellar symptoms are the harbinger to the diagnosis of primary malignancy. The abnormal vascularity and growth promoting microenvironment of pituitary adenomas may encourage metastatic seeding and proliferation of these "collision tumours". Here, we present a case of a breast carcinoma metastasis to a pituitary null-cell adenoma in the setting of immunotherapy. Infundibular thickening in the setting of immunotherapy is often ascribed to hypophysitis, but our case highlights that metastatic spread should be part of the differential diagnosis.
肿瘤转移至肿瘤是一种罕见的事件,特别是在垂体。转移至垂体腺瘤最常发生在疾病晚期,常表现为视野缺损和腺垂体功能减退。最常见的原发性癌症是肺癌、乳腺癌和肾癌,它们最常沉积在泌乳素瘤、生长激素瘤和促性腺激素瘤中。在近 40%的病例中,鞍区症状是原发性恶性肿瘤的先兆。垂体腺瘤异常的血管生成和促进生长的微环境可能会促进这些“碰撞肿瘤”的转移播种和增殖。在这里,我们报告了一例在免疫治疗背景下发生的乳腺癌转移至垂体无细胞瘤的病例。免疫治疗背景下的漏斗增厚通常归因于垂体炎,但我们的病例强调转移性播散应作为鉴别诊断的一部分。